Pharmaceutical

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Aug 1, 2024 - 04:00
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Read the original article

Tags:

Previous Article

Magazine: Left in limbo: when pharma halts rare disease research

Next Article

Imunon’s shares soar after IL-12 therapy success in Phase II trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China’s NMPA grants conditional approval for AstraZeneca’s Calquence

China’s NMPA grants conditional approval for AstraZenec...

Mar 25, 2023

Stalica raises $17.5m to advance neurology programmes

Stalica raises $17.5m to advance neurology programmes

Jan 17, 2024

STAT+: The clock is ticking, and Cytokinetics is running out of December

STAT+: The clock is ticking, and Cytokinetics is runnin...

Dec 25, 2023